Systemic Hyperinflammation in Cardiac Surgery Protect Your Surgery Results With CytoSorb you can pursue these therapeutic targets: (supported by clinical and preclinical * data) CytoSorb Therapy – REGAIN CONTROL Modulation of immune response (1) Stabilization of hemodynamics (1,2) Improvement in organ functions (1,2) Reduction in complications (3)
2
Embed
Systemic Hyperinflammation in Cardiac Surgery · References (* preclinical data): 1. Traeger K et al., Int J Artif Organs 2016; 39(3): 141 - 6 2. Traeger K et al., Int J Artif Organs
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Therapeutic approach Target: Shock reversal
Systemic Hyperinflammation in Cardiac Surgery Protect Your Surgery Results
With CytoSorb you can pursue these therapeutic targets:(supported by clinical and preclinical * data)
• Quick integration into HLM, CRRT and ECMO circuits • No activation of coagulation and complement system• No relevant elimination of albumin and platelets (9)
The appropriate concept for every situation: CytoSorb
To reduce inflammatory activation in high-risk patients/surgery with HLM
To regain control in organ dysfunction caused by hyperinflammation
Intraoperative use Postoperative use
Visit http://literature.cytosorb.com for an overview of all references
CytoSorbents Europe GmbH
Müggelseedamm 13112587 Berlin | Germany T +49 30 65 49 91 45 F +49 30 65 49 91 46 [email protected]
CytoSorb should only be administered by personnel who have been properly trained in administration of extracorporeal therapies.
CytoSorb is not available for commercial sale in USA.
References (* preclinical data):1. Traeger K et al., Int J Artif Organs 2016; 39(3): 141 - 62. Traeger K et al., Int J Artif Organs 2017; 40(5): 240 - 93. Deppe AC et al., Z Herz-Thorax-Gefäßchir 2016; 30(4): 254 - 94. Faenza S et al., Crit Care 2016; 20(Suppl 2):P192 *5. Buettner S et al., Blood Purif 2017; 44(1): 30 - 16. Traeger K et al., EuroELSO. Glasgow 20167. Gruda M et al., PLoS One 2018; 13(1):e0191676 *
8. Venkataraman R et al., Blood Purif 2004; 22: 143 - 9 *9. Bernardi MH et al., Crit Care 2016; 20(1): 9610. Kuntsevich VI et al., Artif Cells Blood Subset Biotechnol 2009; 37(1): 45 - 7 *